Clopidogrel thiolactone - CAS 1147350-75-1
Catalog number: 1147350-75-1
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C16H16ClNO3S
Molecular Weight:
337.82
COA:
Inquire
Targets:
P2Y Receptor
Description:
The thiolactone form of Clopidogrel that could be an effective antiplatelet agent for behaving as an inhibitor of P2Y12 receptor.
Purity:
98%
Appearance:
Powder
Synonyms:
Clopidogrel thiolactone; 2-oxoclopidogrel; UNII-0IX303KU54; 2-oxo-clopidogrel; 0IX303KU54
Solubility:
10 mM in DMSO
Storage:
-20ºC Freeze
MSDS:
Inquire
Application:
The thiolactone form of Clopidogrel that could be an effective antiplatelet agent for behaving as an inhibitor of P2Y12 receptor.
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Quantity:
Milligrams-Grams
InChIKey:
JBSAZVIMJUOBNB-WUJWULDRSA-N
InChI:
InChI=1S/C16H16ClNO3S/c1-21-16(20)15(11-4-2-3-5-12(11)17)18-7-6-13-10(9-18)8-14(19)22-13/h2-5,8,13,15H,6-7,9H2,1H3/t13?,15-/m0/s1
Canonical SMILES:
COC(=O)C(C1=CC=CC=C1Cl)N2CCC3C(=CC(=O)S3)C2
1.Identification of alcohol-dependent clopidogrel metabolites using conventional liquid chromatography/triple quadrupole mass spectrometry.
Hu ZY;Laizure SC;Herring VL;Parker RB Rapid Commun Mass Spectrom. 2014 Jun 15;28(11):1285-92. doi: 10.1002/rcm.6901.
RATIONALE: ;Clopidogrel (CLO) is a prodrug used to prevent ischemic events in patients undergoing percutaneous coronary intervention or with myocardial infarction. A previous study found ethyl clopidogrel (ECLO) is formed by transesterification of CLO when incubated with alcohol in human liver microsomes. We hypothesize that ECLO will be subject to further metabolism and developed an assay to identify its metabolites.;METHODS: ;A liquid chromatography/triple quadrupole mass spectrometry (LC/MS/MS) method was developed to identify metabolites of ECLO. According to the predicted metabolic pathway of ECLO, precursor-product ion pairs were used to screen the possible metabolites of ECLO in human liver S9 fractions. Subsequently, the detected metabolites were characterized by the results of product ion scan.;RESULTS: ;In the presence of alcohol, CLO was tranesterified to ECLO, which was further oxidized to form ethylated 2-oxo-clopidogrel and several ethylated thiol metabolites including the ethylated form of the H4 active metabolite.;CONCLUSIONS: ;The ECLO formed by transesterification with alcohol is subject to metabolism by CYP450 enzymes producing ethylated forms of 2-oxo-clopidogrel and the active H4 thiol metabolite.
2.Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel.
Chen CH;Yang JC;Uang YS;Lin CJ Biopharm Drug Dispos. 2012 Jul;33(5):278-83. doi: 10.1002/bdd.1795. Epub 2012 Jun 29.
The interaction between proton pump inhibitors (PPIs) and clopidogrel/prasugrel was investigated. The IC50 values of omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole on the metabolic ratios of 2-oxo-clopidogrel/clopidogrel, H4 (the active metabolite of clopidogrel)/2-oxo-clopidogrel and R-138727 (the active metabolite of prasugrel)/prasugrel thiolactone in human liver microsomes were determined. The antiplatelet activities of clopidogrel and prasugrel were measured with or without PPIs. As a result, most PPIs (except for pantoprazole) inhibited the formation of 2-oxo-clopidogrel with IC50 values of 20-32 μm and inhibited the formation of H4 with IC50 values of 6-20 μm. PPIs inhibited the formation of R-138727 with IC50 values of 9-25 μm. Among the tested PPIs, omeprazole exhibited the highest inhibitory potency on the formation of H4. Omeprazole, esomeprazole and rabeprazole exhibited the highest inhibitory potencies on the formation of R-138727. For platelet aggregation, omeprazole and lansoprazole show higher inhibitory effects on the antiplatelet activity of clopidogrel. On the other hand, omeprazole, esomeprazole and rabeprazole significantly decreased the antiplatelet activity of prasugrel thiolactone.
3.The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway.
Ford NF J Clin Pharmacol. 2016 Dec;56(12):1474-1483. doi: 10.1002/jcph.769. Epub 2016 Jun 22.
The major metabolic pathway of clopidogrel is conversion to carboxylic acid by an esterase (CES1), forming clopidogrelic acid (SR26334) that is inactive. There is agreement on the structure of the active metabolite; however, there are differing views about the mechanism of its formation. Sanofi studied the conversion of clopidogrel to the active metabolite using human liver microsomes. It was concluded that 2-oxo-clopidogrel was formed via CYP3A oxidation. From a subsequent in vitro study by Sankyo of the metabolism of clopidogrel using recombinant DNA CYPs, it was concluded that CYP2C19 was the major oxidative pathway. Such CYPs can give false-negative results particularly with drugs such as clopidogrel that have high first-pass metabolism in the enterocyte. CYP3A is present in the enterocyte but not CYP2C19. However, the view that clopidogrel is a CYP2C19 substrate was reinforced by a finding that omeprazole, a CYP2C19 inhibitor, reduced the ability of clopidogrel to inhibit platelet aggregation. The drug-drug interaction study of clopidogrel with omeprazole had the effect of reducing the area under the curve (AUC) of the clopidogrel active metabolite by 45%. However, a drug interaction study with a CYP3A inhibitor, grapefruit juice, caused a 6-fold reduction in the AUC of the active metabolite.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related P2Y Receptor Products


CAS 129-46-4 Suramin Sodium

Suramin Sodium
(CAS: 129-46-4)

The sodium salt of Suramin which is a P2 purinergic antagonist and has been also found to have the effect in blocking the G protein binds to GPCRs so that it wa...

CAS 389574-19-0 Prasugrel Hydrochloride

Prasugrel Hydrochloride
(CAS: 389574-19-0)

Prasugrel is a platelet inhibitor (IC50=1.8 μM) , as a third-generation thienopyridine.

CAS 216657-60-2 AR-C 118925XX

AR-C 118925XX
(CAS: 216657-60-2)

AR-C126313, a thiouracil derivative, has been found to be a competitive P2Y2 receptor antagonist and could inhibit P2Y2 receptor-induced β-arrestin translocatio...

CAS 274693-27-5 Ticagrelor

Ticagrelor
(CAS: 274693-27-5)

Ticagrelor, the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Used in...

CAS 113665-84-2 Clopidogrel

Clopidogrel
(CAS: 113665-84-2)

Clopidogrel, a thienopyridine derivative, could be used in the prevention and treatment of sorts of arterial circulation disorders caused by platelet aggregatio...

CAS 870544-59-5 BPTU

BPTU
(CAS: 870544-59-5)

BPTU is an allosteric antagonist of P2Y1 (EC50 = 0.06-0.3 μM) that binds receptors outside of the helical bundle. BPTU blocks inhibition of spontaneous contract...

CAS 211427-08-6 Diquafosol tetrasodium

Diquafosol tetrasodium
(CAS: 211427-08-6)

Diquafosol tetrasodium, also referred to Diquas, is aP2Y2receptor agonist that is targeted to treat dry eye disease through rehydration of the ocular surface.

CAS 1448858-83-0 MRS 2693 trisodium salt

MRS 2693 trisodium salt
(CAS: 1448858-83-0)

MRS 2693 trisodium salt is a selective P2Y6 agonist (EC50 = 0.015 μM at the hP2Y6 receptor), with no activity at other P2Y subtypes.

Quick Inquiry

Verification code

Featured Items